Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
US |
|
Beijing Haixin Energy Technology Co Ltd
SZSE:300072
|
CN |
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc. is carving out a distinctive niche in the biotechnology industry with a focus on developing therapies that modulate critical pathways involved in cancer and severe non-cancer indications. Founded in 2005, Syndax has its sights set on innovative epigenetic and immune-oncology treatments, harnessing the power of scientific breakthroughs to target hard-to-treat conditions. The company's primary approach revolves around inhibiting specific enzymes that alter the expression of genes, thereby reprogramming cancer cells to succumb to therapeutic intervention or effectively arming the immune system to target tumors. This strategic focus is not merely theoretical; it is grounded in a robust pipeline of clinical-stage drug candidates, which they steadily advance through focused research and strategic collaborations.
Syndax generates revenue by developing these pioneering treatments and moving them through the rigorous stages of clinical trials towards regulatory approval. The ultimate goal is to bring their breakthrough medications to market, where they can provide significant medical benefits and address unmet needs in the oncology space. Their business model also includes collaborations and partnerships with larger pharmaceutical companies, which often entail milestone payments and royalties. By leveraging these strategic alliances, Syndax not only monetizes its innovations but also gains access to complementary expertise, enhancing its capabilities in developing and commercializing its investigational therapies. Through this two-pronged focus on groundbreaking research and strategic partnerships, Syndax has positioned itself as a dynamic player poised to make significant contributions to the field of medicine.
Syndax Pharmaceuticals Inc. is carving out a distinctive niche in the biotechnology industry with a focus on developing therapies that modulate critical pathways involved in cancer and severe non-cancer indications. Founded in 2005, Syndax has its sights set on innovative epigenetic and immune-oncology treatments, harnessing the power of scientific breakthroughs to target hard-to-treat conditions. The company's primary approach revolves around inhibiting specific enzymes that alter the expression of genes, thereby reprogramming cancer cells to succumb to therapeutic intervention or effectively arming the immune system to target tumors. This strategic focus is not merely theoretical; it is grounded in a robust pipeline of clinical-stage drug candidates, which they steadily advance through focused research and strategic collaborations.
Syndax generates revenue by developing these pioneering treatments and moving them through the rigorous stages of clinical trials towards regulatory approval. The ultimate goal is to bring their breakthrough medications to market, where they can provide significant medical benefits and address unmet needs in the oncology space. Their business model also includes collaborations and partnerships with larger pharmaceutical companies, which often entail milestone payments and royalties. By leveraging these strategic alliances, Syndax not only monetizes its innovations but also gains access to complementary expertise, enhancing its capabilities in developing and commercializing its investigational therapies. Through this two-pronged focus on groundbreaking research and strategic partnerships, Syndax has positioned itself as a dynamic player poised to make significant contributions to the field of medicine.
Revenue Growth: Syndax reported total 2025 revenue of $172.4 million in its first full year as a commercial company, led by strong launches for Revuforj and Niktimvo.
Revuforj Momentum: Revuforj net revenue reached $124.8 million for 2025, with fourth quarter sales up 38% sequentially as demand accelerates in both KMT2A and newly approved NPM1 AML patients.
Niktimvo Outperformance: Niktimvo generated $151.6 million in net revenue in its first 11 months, tracking ahead of benchmarks set by competitors and contributing $42.4 million in collaboration revenue to Syndax.
Profitability Outlook: The company expects to reach profitability with robust revenue growth, stable expenses (guided to ~$400 million in 2026), and a strong cash position of $394 million at year-end.
Clinical Pipeline Progress: Syndax advanced pivotal trials for revumenib and completed Phase II enrollment for axatilimab in IPF, targeting large market opportunities.
Market Share & Competition: Management expressed confidence in capturing dominant share in new indications, citing minimal competitive impact so far and superior product profiles.
